Ayble Health announced a $16 million Series A round for its AI-powered virtual gastrointestinal clinic, adding fresh capital to a category that is trying to prove specialty-focused virtual care can support large chronic-disease populations with more tailored care pathways. The Boston-based company said it treats digestive issues including abdominal pain, bloating, constipation, weight gain and more, and offers patients access to a care team, nutrition tools, gut-brain behavioral therapy and wellness support.
The round was led by Neon, with participation from Unum Ventures, Upfront Ventures, M13, Cleveland Clinic Ventures, DigiTx and Accomplice. Ayble Health said it has now raised more than $27 million in total. The company serves employers, payers and providers, which gives the financing a commercial angle beyond consumer health: this is a business built around institutional distribution and reimbursement relationships rather than direct-to-consumer acquisition alone.
Where the money is going
Founder and CEO Sam Jactel said the financing will be deployed across three areas. First, Ayble plans to advance its machine learning capabilities to deliver what he described as deeper, data-driven personalization across patient enrollment, engagement and clinical pathways. In this framing, AI is being used to refine how patients enter and move through care rather than to replace clinicians.
Second, the company plans to expand its multidisciplinary care model beyond GI into adjacent therapeutic areas, starting with autoimmune conditions including rheumatoid arthritis, psoriasis and autoimmune thyroid disorders. Third, it aims to accelerate its commercial footprint across national health plans, jumbo employers and key benefit platforms.
That expansion thesis rests on the overlap between GI and autoimmune disease. Ayble cited a 2025 study of 141 million patients that found inflammatory bowel disease was associated with 24 distinct autoimmune conditions. Jactel argued that traditional healthcare treats these conditions in isolated silos with 10-minute specialty visits, while Ayble is building a unified platform for overlapping gut and autoimmune conditions.
The market signal
The company is targeting a large cost burden. Ayble said GI conditions affect more than 70 million Americans and drive $136 billion in annual U.S. healthcare spending, while autoimmune conditions add about $106 billion a year in direct U.S. healthcare spend. It also pointed to wait times of up to 40 days for specialty visits.
The signal in this financing is not just that digital health capital is still available, but where it is going: toward companies arguing they can combine evidence-building, specialty workflow and AI-enabled personalization in categories with expensive, fragmented care. Neon’s Kimmy Scotti said Ayble had spent years building clinical evidence before scaling the business, a point that suggests investors are rewarding digital health models that can make a credibility case to health systems, payers and patients before pushing for faster growth.
